Skip to content

PSMA-PET/CT imaging in the EArly detection of Cancer of the Prostate with High Risk Features

PSMA-PET/CT imaging in the EArly detection of Cancer of the Prostate with High Risk Features - PEACH trial

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON50089
Enrollment
60
Registered
2019-06-28
Start date
2019-11-01
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignancy of the prostate Prostate Cancer

Interventions

None listed

Sponsors

Vrije Universiteit Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Men * 45 years with no history of PCa and no prior prostate biopsies with suspected, potentially aggressive PCa due to an elevated PSA-level between 20 and 50 ng/mL are eligible.

Exclusion criteria

Exclusion criteria: - Previous diagnosis of prostate cancer - Previous prostate biopsy - Previous PSMA PET/CT scan

Design outcomes

Primary

MeasureTime frame
OUTCOME MEASURES. It is assessed: 1) the (reduced) number of prostate biopsy procedures in the 18F-PSMA-diagnostic pathway, 2) the (reduced) number of prostate biopsy cores taken, 3) the (increased) number of clinically significant (Gleason score 3 + 4 = 7, 4 + 3 = 7,8-10) prostate cancers detected per prostate biopsy session, 4) the calculated (reduced) number of complicated urinary tract infections such as urosepsis due to prostate biopsy.

Secondary

MeasureTime frame
ND

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)